DIRS.INFO The most relevant business & tech news

☆ Novartis lifts guidance after first-quarter results beat expectations
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: +2 min

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results. In a statement, it said 2024 net sales would likely grow by a high-single to low double-digit percentage with adjusted operating income expected to grow by a low double-digit to mid-teens percentage. It has previously predicted that adjusted operating income would increase by a "high single-digit" percentage with "mid single-digit" sales growth. Quarterly adjusted operating income gained 16% to $4.54 billion, beating an average analyst estimate of about $4.3 billion.

Persons: Bristol Myers, Giovanni Caforio, Joerg Reinhardt, Vas Narasimhan, Sandoz Organizations: Novartis, Institutes, Research, Bristol, Bristol Myers Squibb Locations: Cambridge , Massachusetts, U.S

☆ Jim Cramer shares his thoughts on RTX, Pepsi, Nucor, Novartis and Cadence Design Systems
▼ + stars: | 2024-04-23 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +1 min

RTX : Shares were roughly flat after the aerospace and defense company delivered a quarterly earnings beat and reaffirmed its full-year 2024 outlook for sales, adjusted earnings and free cash flow. He goes out on an absolute high," Jim Cramer said, noting the strength in its Pratt & Whitney division. Nucor : The steelmaker's first-quarter earnings and sales came in lighter than expected, and its current-quarter outlook disappointed, as well. Cramer noted Nucor CEO Leon Topalian is set to appear on "Mad Money" later Tuesday, and he'll be seeking clarity around the impact pricing has had on the company. Cadence Design Systems : The semiconductor design software maker's second-quarter guidance came in light, saying customers are delaying orders due to hardware transition.

Persons: Jim Cramer's, Greg Hayes, Jim Cramer, Cramer, Leon Topalian, he'll, I've, Vas Organizations: CNBC, Club, Pratt & Whitney, PepsiCo, Novartis, Cadence Design Systems Locations: U.S, Swiss

☆ Drugmaker Novartis climbs 4.4% after guidance rise on sales of blockbuster drugs
▼ + stars: | 2024-04-23 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Signage for Novartis AG at a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. Shares of Swiss drugmaker Novartis climbed as much as 4.8% in early deals on Tuesday, after the company raised its full-year guidance following better-than-expected first-quarter results. Novartis' net sales rose 11% in the first three months of the year, while core operating income increased 22% over the same period. Narasimhan said the company continued to advance its drug pipeline in the first quarter, including treatments for prostate cancer and leukemia. "The momentum in our business and pipeline gives us continued confidence in our mid- and long-term growth outlook," he said.

Persons: Vas Narasimhan, Narasimhan Organizations: Novartis AG, Swiss, Novartis Locations: company's, Basel, Switzerland, London

☆ Novartis CEO: Here's why we boosted our full-year guidance
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Here's why we boosted our full-year guidanceVas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.

Persons: Vas Organizations: Novartis Locations: U.S

☆ Watch CNBC's full interview with Novartis CEO Vas Narasimhan on earnings and weight loss drugs
▼ + stars: | 2024-04-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Novartis CEO Vas Narasimhan on earnings and weight loss drugsVas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss what feeds the company's strong guidance, if pricing in the U.S. will involve some friction, and more.

Persons: Vas Organizations: Novartis Locations: U.S

Raymond James raised its price target on Nvidia to $1,100, noting revenue momentum will stay strong. On a more sour note, Bank of America lowered its price target on Boeing to $190, citing risks around the company's ongoing safety issues. He raised his price target by $30 to $160, which suggests more than 25% potential upside for shares. Analyst Bryan Bergin initiated coverage of Mastercard with a buy rating and $545 price target, which indicates 16.2% potential upside. — Pia Singh 5:50 a.m.: Bank of America cuts Boeing price target Boeing's latest troubles made Bank of America even more skeptical on the stock's prospects.

Persons: Raymond James, Berenberg, Andres Castanos, Mollor, — Pia Singh, Bernstein, Johnson, Callum Elliott, Kenvue, Elliott, Lorraine Hutchinson, Hutchinson, Nike's, TD Cowen, Bryan Bergin, Bergin, Blackwell, Srini Pajjuri, Ronald Epstein, Dave Calhoun, Epstein, Fred Imbert Organizations: CNBC, Nvidia, Bank of America, Boeing, Johnson, Nike, Mastercard, Visa, of America, New York Times Locations: Albemarle, underperform, China, Europe, Asia

☆ I quit my blue-collar job and grew 2 ecommerce brands to over $1M in revenue. I finally have financial freedom.
▼ + stars: | 2024-03-01 | by ( Perri Ormont Blumberg | ) www.businessinsider.com time to read: +6 min

I commuted two hours a day to a dirty, physical job and felt unfulfilled. E-commerce fit all these requirements, but besides selling digital albums on iTunes, I had zero experience trying to sell anything. I got started on YouTubeOne night, I found a nearly five-hour-long YouTube video tutorial on private-label brands by Dan Vas. AdvertisementI looked for products to sell that had a balance of great sales potential and low competition. Try not to fall victim to shiny object syndromeAt the beginning of my e-commerce journey, I started three other brands that didn't pan out.

Persons: —, Sydney Bencriscutto, Dan Vas, Dad, Robert T, Ryan Stephens Organizations: Service, Business, iTunes, YouTube Locations: Milwaukee

☆ The 3 worst things virtual assistants have to deal with and how to avoid them, according to a successful VA coach
▼ + stars: | 2024-02-24 | by ( Robin Madell | ) www.businessinsider.com time to read: +5 min

Hannah Dixon, a virtual assistant coach, discusses the three worst parts of the profession. AdvertisementThis as-told-to essay is based on a conversation with Hannah Dixon, a 36-year-old virtual assistant coach, recruiter, and founder of The Virtual Excellence Academy, living in Mexico. After "falling" into becoming a virtual assistant 10 years ago, I did the job for years juggling admin, tech, and creative tasks for clients worldwide. While virtual administrative assistant work is a very needed service, it's just one piece of a large and ever-expanding puzzle. Are you a virtual assistant and would like to share your story?

Persons: Hannah Dixon, Dixon, VAs, —, It's, who've, upskilling —, it's, I've, Logan Organizations: Service, Virtual Excellence Academy, VAs Locations: Mexico, VAs, mlogan@businessinsider.com

☆ Novartis misses Q4 net income expectations, extends forecast
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Swiss drugmaker Novartis reported a 6% gain in fourth-quarter adjusted net income on Wednesday, helped by cost cuts and strong growth of recently launched drugs. Core net income for the quarter came in at $3.13 billion, it said in a statement, missing analysts' estimate of about $3.3 billion, as per LSEG data. Novartis also extended its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings. CEO Vas Narasimhan previously led a push to cut jobs and focus on fewer therapeutic areas and geographic markets, before spinning off and listing generic drugs business Sandoz late last year.

Persons: Sandoz, Vas Narasimhan Organizations: Novartis

☆ Novartis CEO: Growth drivers performing well, but product exclusivity losses creating headwinds
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Growth drivers performing well, but product exclusivity losses creating headwindsVas Narasimhan, CEO of Novartis, discusses fourth-quarter results, weight loss drugs and the company's U.S. targets.

Organizations: Novartis Locations: U.S

☆ Top pharma CEO says preparedness for a new pandemic has not improved
▼ + stars: | 2024-01-17 | by ( Vicky Mckeever | ) www.cnbc.com time to read: 1 min

Vas Narasimhan, chief executive officer of Novartis AG, listens during a panel session on the opening day of the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 22, 2019. Vas Narasimhan, CEO of pharmaceutical firm Novartis, told CNBC Tuesday that he didn't believe there had been much improvement in preparedness for pandemics in the wake of the Covid crisis. "I'm sad to say, I don't think we've improved unfortunately," said Narasimhan, speaking at the World Economic Forum in Davos, Switzerland. He explained that there did not appear to be the continued level of investment as hoped for, during this "inter-pandemic" period. "Now that we're past the pandemic — and really because of the feats of our industry, companies coming up with incredible mRNA vaccines and diagnostic tools — we're back to almost no investment from governments," Narasimhan said.

Persons: Vas, Narasimhan Organizations: Novartis AG, Economic, Novartis, CNBC Locations: Davos, Switzerland

☆ Here's an exclusive look at the 16-slide pitch deck that got Bolt cofounder Ryan Breslow to bet on a male birth control startup
▼ + stars: | 2024-01-16 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read previewThe market for male birth control is growing. AdvertisementThe reversal of Roe v. Wade in 2022 has prompted many people to reevaluate their birth control choices, NEXT CEO L.R. Fox pointed to the increasing rate of vasectomies among younger men and men without children as more evidence that they want to participate in the decision-making process around birth control. Scientists are also working on a hormonal male birth control pill and a topical hormonal gel.

Persons: —, Ryan Breslow's, Roe, Wade, L.R, Fox, I'm, Contraline, Vasalgel Organizations: Service, Business, Sciences, NEXT, Venture, Particular Ventures, Keno, Ventures, Fund, Fox, Sciences isn't, Parsemus Foundation, Food and Drug Administration Locations: Africa

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Novartis lifts sales growth target to 5% per year through 2027
▼ + stars: | 2023-11-28 | by ( Ludwig Burger | ) www.reuters.com time to read: +1 min

The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo Acquire Licensing RightsCompanies Novartis AG FollowSandoz GmbH FollowFRANKFURT, Nov 28 (Reuters) - Novartis (NOVN.S) has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after it sold off its generic-drugs business. The medium-term target, which excludes any foreign exchange effects, is mainly driven by six drugs, led by Kisqali, it said in a presentation on Tuesday. The sales forecast, up from a previous revenue growth target of 4% through 2027, is also underpinned by demand for Pluvicto, a precision radiotherapy against prostate cancer, and self-administered multiple sclerosis (MS) shot Kesimpta. Reporting by Ludwig Burger; Editing by Miranda Murray and Miral FahmyOur Standards: The Thomson Reuters Trust Principles.

Persons: Charles Platiau, Kisqali, Vas, Kesimpta, drugmaker, Sandoz, Ludwig Burger, Miranda Murray, Miral Organizations: Swiss, Novartis, REUTERS, Companies Novartis, Sandoz, FRANKFURT, Thomson Locations: Rueil, Malmaison, Paris, France, Basel, Swiss

☆ 3 virtual assistants who make up to $8,000 a month in revenue share how they got started
▼ + stars: | 2023-10-20 | by ( Ella Hopkins | ) www.businessinsider.com time to read: +4 min

She built a "strong personal brand," she said, which meant tailoring her presence and wording to what the clients she wanted. Shannon Blanchard started working as a virtual assistant in January 2021 and wanted to work with creatives and web designers. Instead of cold-pitching her services, she'd comment on the Instagram stories and posts of clients she wanted to work with. Read more: I made up to $6,300 a month working 3 hours a day as a virtual assistant. Anna Christine, @annachristine.photoMary Carrasquillo started her virtual-assistant business in December 2020, and was booking more than $8,000 a month in monthly revenue by January 2022.

Persons: VAs, Hannah Dixon, Hannah Dixon Hannah Dixon, who's, Dixon, Read, I've, Shannon Blanchard, Blanchard, I'd, Here's, Mary Carrasquillo, Anna Christine, @annachristine.photo Mary Carrasquillo, Carrasquillo Locations: VAs, Instagram

☆ Novartis' Sandoz valued at $11.2 bln in market debut
▼ + stars: | 2023-10-04 | by ( ) www.reuters.com time to read: +1 min

A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 4 (Reuters) - Sandoz (SDZ.S) made its market debut with a lower-than-expected valuation of 10.3 billion Swiss francs ($11.2 billion) on Wednesday, after the generic and biosimilar drugmaker was spun off from Swiss pharmaceutical company Novartis (NOVN.S). Deutsche Bank had said Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, would likely be valued at $11-$13 billion, while brokerage Berenberg had forecast $17-$26 billion. The shares, which opened at 24 Swiss francs, became members of the Swiss Performance Index and the Swiss Leader Index, among other stock market gauges, and American depositary receipts also started trading on Wednesday. Novartis shareholders received one Sandoz share for every five Novartis shares they held as part of the transaction.

Persons: Brian Snyder, drugmaker, Sandoz, Berenberg, Vas Narasimhan, Ludwig Burger, Tristan Veyet, Clarence Fernandez, Mark Potter Organizations: Novartis, Research, REUTERS, Sandoz, Analysts, Deutsche Bank, Swiss, Thomson Locations: Cambridge , Massachusetts, U.S, Swiss, generics

☆ Novartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines company
▼ + stars: | 2023-10-04 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Spinoffs will see us succeed as a pure-play innovative medicines companyNovartis CEO Vas Narasimhan discusses what the spinoff of the company's Sandoz unit means for the organization.

Persons: Vas, Sandoz Organizations: Novartis

☆ Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO
▼ + stars: | 2023-10-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis positioning is now best-suited for long-term gains and returns after spin-off, says CEONovartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's growth prospects.

Persons: Vas Narasimhan, Sandoz Organizations: Novartis

☆ Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off
▼ + stars: | 2023-10-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin offVas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.

Organizations: Novartis, Sandoz Locations: Sandoz

☆ Watch CNBC's full interview with Novartis CEO Vas Narasimhan
▼ + stars: | 2023-10-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Novartis CEO Vas NarasimhanNovartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's growth prospects.

Persons: Vas Narasimhan, Sandoz Organizations: Novartis

☆ I'm a virtual assistant who left my legal career because I needed more flexibility at work. Here's how I got started and outsource to other VAs.
▼ + stars: | 2023-09-18 | by ( Ella Hopkins | ) www.businessinsider.com time to read: +5 min

I quit my job and started a VA courseI took the plunge and left my job. In my legal job, I'd worked with a VA. I found clients through VA networksI joined lots of different Facebook groups, freelancer groups, and networking groups to build my network. If there were aspects of client work that I didn't like doing, or it wasn't my forte, then I would delegate. I time block my whole week and I use Asana, a project-management tool, to keep a record of my client work.

Persons: Laura Leach, I'd, We'd, I'm, That's, I've Organizations: HR Locations: Yorkshire, England, VAs, Harrogate

☆ I make up to $6,000 a month selling Udemy courses for virtual assistants. Here's how I got started.
▼ + stars: | 2023-08-22 | by ( Sasha Weilbaker | ) www.businessinsider.com time to read: +6 min

Erin Booth has created courses on Udemy to help other virtual assistants skill up. She started with one course and now has 24 that earn her up to $6,000 a month in passive income. Her advice for creating courses on Udemy is to seek out a niche and be aware of your competition. I've been a virtual assistant since 2012, and I started creating online courses for other virtual assistants in 2018. Since I've opted into their promotional program, Udemy markets my courses for me on their platform but discounts the courses heavily.

Persons: Erin Booth, I've, I'd, VAs, It's, you've Organizations: Service, YouTube Locations: Wall, Silicon, Washington ,, VAs

☆ Novartis plans Sandoz spin-off around Oct. 4, proposes share
▼ + stars: | 2023-08-18 | by ( ) www.cnbc.com time to read: +1 min

Novartis on Friday proposed to offer shareholders one Sandoz share for every five Novartis shares as it said it planned to spin off the generic medicines division on or around Oct. 4. The Swiss drugmaker invited shareholders to an extraordinary general meeting on Sept. 15 after its board of directors unanimously endorsed and recommended the proposed spin-off, the company said in a statement. "If Novartis shareholders approve the proposed special distribution at the EGM, the Spin-off will be implemented through the distribution of a dividend-in-kind of Sandoz shares to Novartis shareholders, and of Sandoz ADRs (American Depositary Receipts) to Novartis ADR holders," it said. Sandoz, which accounted for about 10% of group core operating profit of $16.7 billion in 2022, was put under a strategic review by Novartis CEO Vas Narasimhan in 2021 following mounting pricing pressures in the U.S. off-patent drug sector. Novartis announced plans for the spin-off in August 2022.

Persons: Sandoz, Vas Organizations: Novartis, EGM, Sandoz, Sandoz ADRs Locations: Swiss, U.S

☆ Novartis CEO: We expect our six key drugs to grow ahead of analyst expectations
▼ + stars: | 2023-07-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis CEO: We expect our six key drugs to grow ahead of analyst expectationsNovartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss what's driving the company's earnings beats, the company's newest technologies, and the 'war for talent.'

Persons: Vas Narasimhan Organizations: Novartis

☆ I've made 6 figures a year as a virtual assistant. Here are my 5 best tips on how to break into the job.
▼ + stars: | 2023-07-07 | by ( Robin Madell | ) www.businessinsider.com time to read: +10 min

Dixon says that virtual assistants need to provide a VIP client experience to find success. Becoming a successful virtual assistant — or VA — requires more than a laptop and a dream. The number-one thing that contributed to my, and my learners', six-figure success was providing a quality client experience. You can boost client experience by making things easier for them. If you would like to share your experience as a virtual assistant please reach out to Jenna Gyimesi at jgyimesi@insider.com

Persons: Hannah Dixon, Dixon, —, It's, I've, VAs, I'm, Shakespeare, Jenna Gyimesi Organizations: Service Locations: Guanajuanto, Mexico, VAs

Search resuls for: "Vas"

25 mentions found